4-[(3-Thiophen-2-ylphenyl)methyl]morpholine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(3-Thiophen-2-ylphenyl)methyl]morpholine
• 英文别名: 4-[(3-thiophen-2-ylphenyl)methyl]morpholine
• 化学式: C₁₅H₁₇NOS
• 分子量: 259.4
• InChiKey: VENGHTDOSCBEOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  40.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT
  申请人：4SC AG

  公开号：EP3781159A1

  公开（公告）日：2021-02-24
• PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER
  申请人：4SC AG

  公开号：EP3781557A1

  公开（公告）日：2021-02-24
• [EN] PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER<br/>[FR] PRODUITS DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN INHIBITEUR D'HISTONE DÉSACÉTYLASE (HDAC) ET UN AGONISTE DE TLR7 ET/OU UN AGONISTE DE TLR8 POUR LE TRAITEMENT DU CANCER
  申请人：4SC AG

  公开号：WO2019197682A1

  公开（公告）日：2019-10-17

  The invention relates to pharmaceutical combination products comprising an HDAC inhibitor, e.g. (E)-N-(2-amino-phenyl)-3-1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}- acrylamide as well as salts and or solvents thereof and TLR7 agonist and/or TLR8 agonist for the treatment of cancer. The present invention also relates to methods of treatment of patients suffering from cancer with these pharmaceutical combination products.
• [EN] COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT<br/>[FR] COMBINAISON COMPRENANT UN INHIBITEUR DE HDAC, UN INHIBITEUR DE LAG-3 ET UN INHIBITEUR DE PD-1 OU UN INHIBITEUR DE PD-L1 POUR LE TRAITEMENT DU CANCER
  申请人：4SC AG

  公开号：WO2019202001A1

  公开（公告）日：2019-10-24

  The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for the treatment of cancer.
• [EN] COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT<br/>[FR] COMBINAISON COMPRENANT UN INHIBITEUR DE HDAC, UN INHIBITEUR DE CTLA-4 ET UN INHIBITEUR DE PD-1 OU UN INHIBITEUR DE PD-L1 POUR LE TRAITEMENT DU CANCER
  申请人：4SC AG

  公开号：WO2021064188A1

  公开（公告）日：2021-04-08

  The invention relates to medical uses of an HDAC inhibitor of the below general formula I, wherein R1 to R7 are as described herein, or a salt or solvate thereof in combination with CTLA-4 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for the treatment of cancer. (Formula)